The Future is Getting Personal: 7 Promising Gene and Cell Therapies for Parkinson’s Disease

If you’ve been keeping your ear to the ground in the world of Parkinson’s research, you’ve probably heard whispers (or shouts) about gene and cell therapies. These aren’t science fiction anymore. They’re real, they’re happening, and they could change everything. Right now, scientists and biotech companies are working on a wave of therapies that go beyond simply easing symptoms. They’re aiming to tackle the root causes—like the clumping of alpha-synuclein protein, dopamine cell loss, and genetic glitches. Some even hope to slow down or stop the disease altogether. Here’s a quick tour of seven of the most exciting therapies currently being tested: 1. BIIB122 by Denali Therapeutics – Taking Aim Early This is a pill (yes, a pill!) designed to switch off a protein called LRRK2, which goes haywire in many people with Parkinson’s. A big international trial called LUMA is underway to see if it can slow down early-stage Parkinson’s. Previous tests showed it was safe and promising—so now, all eyes are on whether it can truly delay progression. 2. AB-1005 by AskBio – Nourishing Neurons This is a one-time gene therapy that delivers GDNF, a natural brain “fertiliser” for dopamine cells. It’s injected directly into the brain (a bit intense, but potentially powerful). Early results looked good, and a new trial across the US, UK, and Europe is testing it in people with moderate Parkinson’s. Bonus: It seems to improve ON/OFF times without causing serious side effects. 3. UB-312 by Vaxxinity – The Vaccine Approach Rather than delivering proteins or genes, this one trains your immune system to fight off toxic forms of alpha-synuclein—the troublemaker protein in Parkinson’s. In early trials, people who developed antibodies saw improvements in daily living scores. No major side effects, and the science suggests it’s hitting the right target. 4. PR001 by Prevail Therapeutics/Eli Lilly – For GBA1 Gene Carriers Some people with Parkinson’s carry mutations in the GBA1 gene, which messes with cell clean-up systems. PR001 is a gene therapy designed just for them. It’s being tested as a single-dose treatment and monitored for five years. There were early bumps (a serious side effect paused the trial), but after some adjustments, it's back on track and looks promising. 5. Bemdaneprocel by BlueRock Therapeutics – A Cell Transplant Revolution Think of this as a fresh start: scientists grow dopamine-producing brain cells from stem cells and transplant them into the brain. Early trials showed big improvements in motor symptoms, especially in people who got the higher dose. A large phase 3 trial is now on the way, and if it works, this could be one of the most transformative treatments yet. 6. AAV-GAD by MeiraGTx – Boosting Brain Chemistry This one boosts GABA, a calming chemical in the brain. It’s a gene therapy delivered in a single, minimally invasive surgery. In early tests, it significantly improved motor scores and had no serious side effects. It’s now headed into long-term follow-up and is almost ready for a full-scale phase 3 trial. 7. The Bigger Picture These therapies are still in trials, which means they’re not yet available on the market—but progress is fast. Each approach offers a different way to tackle Parkinson’s, from genetic editing and brain cell restoration to immune-based strategies. Together, they represent a hopeful shift away from short-term fixes toward long-term change. We’re not there yet. But if this pipeline delivers, the future could be radically different for people with Parkinson’s.